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Abstract: High-mobility group box protein-1 (HMGB-1) plays a central role in the inflammatory
network, and uncontrolled chronic inflammation can lead to excessive scarring. The aim of this study
was to evaluate the anti-inflammatory effects of polydeoxyribonucleotide (PDRN) on scar formation.
Sprague-Dawley rats (n = 30) underwent dorsal excision of the skin, followed by skin repair. PDRN
(8 mg/kg) was administered via intraperitoneal injection for three (PDRN-3 group, n = 8) or seven
(PDRN-7 group, n = 8) days, and HMGB-1 was administered via intradermal injection in addition
to PDRN treatment for three days (PDRN-3+HMGB-1 group; n = 6). The scar-reducing effects of
PDRN were evaluated in the internal scar area and by inflammatory cell counts using histology and
immunohistochemistry. Western blot, immunohistochemistry and immunofluorescence assays were
performed to observe changes in type I and type III collagen and the expression of HMGB-1 and
CD45. Treatment with PDRN significantly reduced the scar area, inflammatory cell infiltration and the
number of CD45-positive cells. In addition, the increased expression of HMGB-1 observed in the sham
group was significantly reduced after treatment with PDRN. Rats administered HMGB-1 in addition
to PDRN exhibited scar areas with inflammatory cell infiltration similar to the sham group, and the
collagen synthesis effects of PDRN were reversed. In summary, PDRN exerts anti-inflammatory and
collagen synthesis effects via HMGB-1 suppression, preventing scar formation. Thus, we believe that
the anti-inflammatory and collagen synthesis effects of PDRN resulted in faster wound healing and
decreased scar formation.
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1. Introduction
Inflammation is an inevitable first step in the process of wound healing and is closely related
to scar formation. However, continuous and chronic inflammation stimulates the secretion of
pro-inflammatory cytokines and causes excessive scarring [1–4]. In one prior study involving a
scarless fetal wound-healing model, scar formation was caused by the injection of mast cells [5].
In addition, despite the observation that neutrophil depletion did not alter wound-breaking strength or
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collagen deposition, neutrophil depletion resulted in wounds that healed in a more organized fashion
compared with normal wounds [6]. Furthermore, another previous study revealed that macrophage
depletion also reduced scar formation [7]. Hence, we hypothesized that the inhibition of inflammatory
cell infiltration could be a factor in reducing scar formation.
The sustained infiltration of immune cells during prolonged and intense inflammation contributes
to the continuous growth of keloid lesions [8,9]. Moreover, keloid growth involves an abnormal
response to inflammation [4,10,11]. In particular, extracellular high-mobility group box protein-1
(HMGB-1) plays a central role in the inflammatory network, as it is induced by a number of cytokines
and can in turn induce a series of inflammatory reactions [12]. HMGB-1 can stimulate inflammation by
binding to several receptors and acts as a potent inflammatory cytokine [13]. Although there have been
few studies on the relationship between HMGB-1 and fibrosis or scarring, the serum level of HMGB-1
has been positively correlated with skin thickness in systemic sclerosis [14]. Furthermore, icariin, which
is used to treat erectile dysfunction, has been shown to reduce liver fibrosis in a thioacetamide-induced
liver fibrosis model by antagonizing the increase in HMGB-1 in addition to other mechanisms [15].
Polydeoxyribonucleotide (PDRN) is composed of a mixture of nucleotides extracted from trout
sperm. PDRN exerts anti-inflammatory effects by inhibiting mast cell degranulation and inflammatory
cytokines [16,17]. A previous study reported that PDRN administration reduced pro-inflammatory
mediators, such as tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and HMGB-1 [18].
Although it could be hypothesized that PDRN may reduce scarring by down-regulating inflammatory
reactions and HMGB-1, no previous studies have investigated the relationship between PDRN and
scarring. Accordingly, the aim of this study was to evaluate the anti-inflammatory effects of PDRN,
including reduced infiltration of inflammatory cells and HMGB-1 expression, on scar formation via
short-duration administration.
2. Results
2.1. Polydeoxyribonucleotide Decreases Scar Size in Incisional Scar Tissue in Rats
On Day 7 of the postoperative period, all groups exhibited complete re-epithelialization and
the formation of granulation tissue, as demonstrated by hematoxylin and eosin (H&E) and Masson’s
trichrome (M-T) staining (Figure 1A). Although the sham group displayed active inflammation with
abundant inflammatory cells and fewer collagen fibers on Day 14 of the postoperative period, the
PDRN-3 and PDRN-7 groups exhibited lower inflammatory cell infiltration with collagen fibers in the
scar area in the H&E- and M-T-stained tissues (Figures 1B and 2).
To estimate the scar area and the degree of granulation tissue formation, only the boundary of the
scar area that covered below the epidermis and above the panniculus carnosus was measured. In each
wound, the scar and/or granulation tissue areas were estimated from two H&E-stained tissue sections
representing different areas of the same wound. Each measurement is shown as the mean ± SEM.
In the quantitative analysis of the scar area, the scar sizes of the sham, PDRN-3, and PDRN-7 groups
were 51,272 ± 5793 µm2, 13,201 ± 2243 µm2, and 21,329 ± 1518 µm2, respectively, on Day 7 of the
postoperative period (* p < 0.05, *** p < 0.001; Figure 1C), while, on Day 14 of the postoperative period,
the scar sizes decreased to 35,368 ± 3511 µm2, 12,304 ± 1842 µm2, and 13,291 ± 1076 µm2, respectively
(** p < 0.01, *** p < 0.001; Figure 1C). These results indicated that PDRN administration reduced the
scar size compared with the sham group.
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Figure 1. H&E- and M-T-stained tissues from the sham, Polydeoxyribonucleotide (PDRN)-3, and 
PDRN-7 groups on Days 7 and 14 (magnification, 40×). (A) All groups exhibited complete re-
epithelialization and the formation of granulation tissue on Day 7. However, the PDRN-3 group 
showed the narrowest granulation tissue area among all groups. (B) Hematoxylin and eosin (H&E)- 
and Masson’s trichrome (M-T)-stained tissues from the sham, PDRN-3, and PDRN-7 groups on Day 
14 (magnification, 40×). The sham group continued to show a wide granulation tissue area with 
inflammation. However, the PDRN-3 and PDRN-7 groups showed more collagen deposition within 
narrower scar areas, as demonstrated by M-T staining. (C) Quantitative analyses of the scar areas in 
each treatment group. The scar areas were significantly narrower in the PDRN-3 and PDRN-7 groups 
than in the sham group on Days 7 and 14. However, no significant difference in scar size was observed 
between the PDRN-3 and PDRN-7 groups on Day 7 or 14 (* p < 0.05, ** p < 0.01, *** p < 0.001). 
 
Figure 2. The sham group still exhibited granulation tissue and fewer collagen fibers with 
inflammatory cell infiltration on Day 14. However, the PDRN-treated groups demonstrated reduced 
inflammatory cell infiltration and collagen fibers (arrows) within the scar area. 
  
Figure 1. H&E- and M-T-stained tissues from the sham, Polydeoxyribonucleotide (PDRN)-3, and
PDRN-7 groups on Days 7 and 14 (magnification, 40×). (A) All groups exhibited complete
re-epithelialization and the formation of granulation tissue on Day 7. However, the PDRN-3 group
showed the narrowest granulation tissue area among all groups. (B) Hematoxylin and eosin (H&E)-
and Masson’s trichrome (M-T)-stained tissues from the sham, PDRN-3, and PDRN-7 groups on
Day 14 (magnification, 40×). The sham group continued to show a wide granulation tissue area with
inflammation. However, the PDRN-3 and PDRN-7 groups showed more collagen deposition within
narrower scar areas, as demonstrated by M-T staining. (C) Quantitative analyses of the scar areas in
each treatment group. The scar areas were significantly narrower in the PDRN-3 and PDRN-7 groups
than in the sham group on Days 7 and 14. However, no significant difference in scar size was observed
between the PDRN-3 and PDRN-7 groups on Day 7 or 14 (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Figure 2. The sham group still exhibited granulation tissue and fewer collagen fibers with inflammatory
cell infiltration on Day 14. However, the PDRN-treated groups demonstrated reduced inflammatory
cell infiltration and collagen fibers (arrows) within the scar area.
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2.2. Polydeoxyribonucleotide Decreases Inflammatory Cell Infiltration in Incisional Scar Tissue in Rats
To observe inflammatory cell infiltration within the scar tissue, we performed CD45
immunofluorescence staining on tissue collected on postoperative Day 7. More CD45-expressing
leukocytes were detected in the sham group than in the PDRN-3 and PDRN-7 groups (Figure 3A).
The number of inflammatory cells was calculated from four serial H&E-stained tissue sections from
within the dermis of the scar area (Figure 3B). On Day 7 of the postoperative period, the mean numbers
of inflammatory cells within the scar tissue were 21.16 ± 2.49, 13.47 ± 1.77, and 14.31 ± 2.28 in the
sham, PDRN-3, and PDRN-7 groups, respectively. On Day 14 of the postoperative period, the mean
numbers of inflammatory cells within the scar tissue were 15.34 ± 1.81, 7.53 ± 1.02, and 8.00 ± 1.12 in
the sham, PDRN-3, and PDRN-7 groups, respectively. The numbers of inflammatory cells on Days 7
and 14 were significantly lower in the PDRN-3 and PDRN-7 groups than the sham group (* p < 0.05,
*** p < 0.001; Figure 3C).
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Figure 3. (A) Immunofluorescence analysis of CD45-expressing leukocytes on Day 7 (magnification, 
400×). The sham group exhibited abundant cellular infiltration, and the majority of the cells were 
CD45-positive (green) leukocytes. The PDRN-3 and PDRN-7 groups exhibited diminished cellular 
infiltration and CD45-positive leukocytes. (B) Inflammatory cell infiltration in the scar area, as 
demonstrated by H&E staining (magnification, 400×). On Days 7 and 14, the sham group exhibited 
significant inflammatory cell infiltration into the scar area compared with the PDRN-3 and PDRN-7 
groups. (C) Comparison of inflammatory cell counts. The infiltration of inflammatory cells in the scar 
area was lower in the PDRN-treated groups than in the sham group on Days 7 and 14 (* p < 0.05, *** 
p < 0.001). 
2.3. Polydeoxyribonucleotide Decreases HMGB-1 Expression in Incisional Scar Tissue in Rats 
Inflammatory cells were clearly observed within the scar tissue following staining for high 
mobility group box-1 (HMGB-1). On Day 7 of the postoperative period, increased HMGB-1 protein 
expression was observed in the sham group, whereas the PDRN-3 and PDRN-7 groups exhibited 
decreased HMGB-1 protein expression within the narrow scar areas. On Day 14 of the postoperative 
period, the sham group continued to exhibit high HMGB-1 expression in the wide scar areas, whereas 
the PDRN-3 and PDRN-7 groups showed markedly decreased HMGB-1 expression and only a small 
number of inflammatory cells (Figure 4A). Semi-quantitative analysis indicated that, on Days 7 and 
14, the PDRN-3 and PDRN-7 groups exhibited significantly lower HMGB-1 protein expression than 
the sham group (* p < 0.05, ** p < 0.01, *** p < 0.001; Figure 4B). 
2.4. HMGB-1 Administration Reverses the Anti-Inflammatory and Collagen Synthesis Effects of PDRN 
We next examined whether HMGB-1 administration could reverse the effects of PDRN. On Day 
7 of the postoperative period, the sham and PDRN-3 + HMGB-1 groups exhibited wider granulation 
tissue areas than did the PDRN-3 group (Figure 5A). The sham and PDRN-3 + HMGB-1 groups 
continued to show higher inflammation with wider scar areas on Day 14 of the postoperative period 
(Figure 5B). Quantitative analysis of the scar area indicated that the scar sizes in the PDRN-3 + 
HMGB-1 group were 44,688 ± 3573 µm2 and 34,593 ± 2751 µm2 on Days 7 and 14, respectively. 
Furthermore, the scar sizes in the PDRN-3 + HMGB-1 group were similar to those of the sham group 
and significantly wider than those of the PDRN-3 group on Days 7 and 14 (* p < 0.05, ** p < 0.01; Figure 
5C). Administration of HMGB-1 to the PDRN-3 group resulted in enhanced inflammation (Figure 
5D). The mean numbers of inflammatory cells in the PDRN-3 + HMGB-1 group were 18.07 ± 2.10 and 
11.75 ± 1.27 on Days 7 and 14, respectively (* p < 0.05, *** p < 0.001; Figure 5E). 
Figure 3. (A) Immunofluorescence analysis of CD45-expressing leukocytes on Day 7 (magnification,
400×). The sham group exhibited abundant cellular infiltration, and the majority of the cells were
CD45-positive (green) leukocytes. The PDRN-3 and PDRN-7 groups exhibited diminished cellular
infiltration and CD45-positive leukocytes. (B) Inflammatory cell infiltration in the scar area, as
demonstrated by H&E staining (magnification, 400×). On Days 7 and 14, the sham group exhibited
significant inflammatory cell infiltration into the scar area compared with the PDRN-3 a d PDRN-7
groups. (C) Comparison of inflammatory cell counts. The infiltrati of infl mmatory cells in the
scar area was lower in the PDRN-treated groups than in the sham group on Days 7 and 14 (* p < 0.05,
*** p < 0.001).
2.3. Polydeoxyribonucleotide Decreases HMGB-1 Expression in Incisional Scar Tissue in Rats
Inflammatory cells were clearly observed within the scar tissue following staining for high
mobility group box-1 (HMGB-1). On Day 7 of the postoperative period, increased HMGB-1 protein
expression was observed in the sham group, w ereas the PDRN-3 and PDRN-7 groups exhibited
decreased HMGB-1 protein expression ithin the narrow scar areas. On Day 14 of the postoperative
period, the sham group continued to exhibit high HMGB-1 expression i the wide scar area , whereas
the PDRN-3 and PDRN-7 groups showed markedly decreased HMGB-1 expression and only a small
number of inflammatory cells (Figure 4A). Semi-quantitative analysis indicated that, on Days 7 and 14,
the PDRN-3 and PDRN-7 groups exhibited significantly lower HMGB-1 protein expression than the
sham group (* p < 0.05, ** p < 0.01, *** p < 0.001; Figure 4B).
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400×). All groups exhibited extracellular expression of HMGB-1, though the PDRN-3 and PDRN-7 
groups displayed weaker expression within the narrow scar areas on Day 7. On Day 14, the sham 
group continued to show high extracellular expression of HMGB-1 in the wide scar areas, whereas 
extracellular expression of HMGB-1 was absent in the PDRN-3 and PDRN-7 groups. (B) Semi-
quantitative analysis of HMGB-1 expression levels. The sham group showed significantly higher 
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< 0.01, *** p < 0.001). 
Figure 4. (A) Immunohistochemistry of high mobility group box-1 (HMGB-1) (magnification, 400×).
All groups exhibited extracellular expression of HMGB-1, though the PDRN-3 and PDRN-7 groups
displayed weaker expression within the narrow scar areas on Day 7. On Day 14, the sham group
continued to show high extracellular expression of HMGB-1 in the wide scar areas, whereas extracellular
expression of HMGB-1 was absent in the PDRN-3 and PDRN-7 groups. (B) Semi-quantitative analysis of
HMGB-1 expression levels. The sham group showed significantly higher levels of HMGB-1 expression
than the PDRN-3 and PDRN-7 groups on Days 7 and 14 (* p < 0.05, ** p < 0.01, *** p < 0.001).
2.4. HMGB-1 Administration Reverses the Anti-Inflammatory and Collagen Synthesis Effects of PDRN
We next examined whether HMGB-1 administration could reverse the effects of PDRN. On Day 7
of the postoperative period, the sham and PDRN-3 + HMGB-1 groups exhibited wider granulation
tissue areas than did the PDRN-3 group (Figure 5A). The sham and PDRN-3 + HMGB-1 groups
continued to show higher inflammation with wider scar areas on Day 14 of the postoperative period
(Figure 5B). Quantitative analysis of the scar area indicated that the scar sizes in the PDRN-3 + HMGB-1
group were 44,688± 3573 µm2 and 34,593± 2751 µm2 on Days 7 and 14, respectively. Furthermore, the
scar sizes in the PDRN-3 + HMGB-1 group were similar to those of the sham group and significantly
wider than those of the PDRN-3 group on Days 7 and 14 (* p < 0.05, ** p < 0.01; Figure 5C).
Administration of HMGB-1 to the PDRN-3 group resulted in enhanced inflammation (Figure 5D).
The mean numbers of inflammatory cells in the PDRN-3 + HMGB-1 group were 18.07 ± 2.10 and
11.75 ± 1.27 on Days 7 and 14, respectively (* p < 0.05, *** p < 0.001; Figure 5E).
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Figure 5. (A) H&E- and M-T-stained tissues from the sham, PDRN 3 and PDRN-3 + HMGB-1 groups 
on Day 7 (magnification, 40×). The PDRN-3 + HMGB-1 group exhibited wider scars compared with 
the PDRN 3 group. (B) H&E- and M-T-stained tissues from the sham, PDRN 3 and PDRN-3 + HMGB-
1 groups on Day 14 (magnification, 40×). Although the rats in the PDRN-3 + HMGB-1 group were 
treated with PDRN, this group exhibited wide scars similar to the sham group on Day 14. The scar-
narrowing effect of PDRN was reversed by administration of HMGB-1. (C) The scar areas in the 
PDRN-3 + HMGB-1 group were significantly wider than those in the PDRN-3 group. Additional 
administration of HMGB-1 reversed the scar-narrowing effect of PDRN (* p < 0.05, ** p < 0.01). (D) 
Inflammatory cell infiltration (arrow) in the PDRN-3 + HMGB-1 group, as demonstrated by H&E 
staining (magnification, 400×). Many inflammatory cells had infiltrated the scar area on Days 7 and 
14. (E) The total inflammatory cell count was significantly higher in the PDRN-3 + HMGB-1 group 
than in the PDRN-3 group on Day 14 (* p < 0.05, *** p < 0.001). This result indicated that the anti-
inflammatory effect of PDRN was reversed by HMGB-1 administration. 
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Figure 5. (A) H&E- and M-T-stained tissues from the sham, PDRN 3 and PDRN-3 + HMGB-1 groups
on Day 7 (magnification, 40×). The PDRN-3 + HMGB-1 group exhibited wider scars compared with
the PDRN 3 group. (B) H&E- and M-T-stained tissues from the sham, PDRN 3 and PDRN-3 + HMGB-1
groups on Day 14 (magnification, 40×). Although the rats in the PDRN-3 + HMGB-1 group
were treated with PDRN, this group exhibited wide scars similar to the sham group on Day 14.
The scar-narrowing effect of PDRN was reversed by administration of HMGB-1. (C) The scar areas in
the PDRN-3 + HMGB-1 group were significantly wider than those in the PDRN-3 group. Additional
administration of HMGB-1 reversed the scar-narrowing effect of PDRN (* p < 0.05, ** p < 0.01).
(D) Inflammatory cell infiltration (arrow) in the PDRN-3 + HMGB-1 group, as demonstrated by
H&E staining (magnification, 400×). Many inflammatory cells had infiltrated the scar area on Days
7 and 14. (E) The total inflammatory cell count was significantly higher in the PDRN-3 + HMGB-1
group than in the PDRN-3 group on Day 14 (* p < 0.05, *** p < 0.001). This result indicated that the
anti-inflammatory effect of PDRN was reversed by HMGB-1 administration.
The synthesis of type I and type II collagen was analyzed by Western blots in the sham, PDRN-3,
and PDRN-3 + HMGB-1 groups. On Day 7 of the postoperative period, type I collagen in the PDRN-3
and PDRN-3 + HMGB-1 groups increased by 1.36 ± 0.07-fold and 1.08 ± 0.03-fold, respectively,
compared with the sham gro p (* p < 0.05, ** p < 0.01; Figure 6A). Type III collagen in the PDRN-3
and PDRN-3 + HMGB-1 groups also increased by 3. 7 ± 0.31-fold and 1.35 ± 0.03-fold, res ectively,
compared with the sham group (** p < 0.01, *** p < 0.001; Figure 6A). On Day 14 of the postoperative
period, type I collagen in the PDRN-3 and PDRN-3 + HMGB-1 groups increased by 1.43± 0.03-fold and
0.75± 0.02-fold, respectively, compared with the sham group (*** p < 0.001; Figure 6B). Type III collagen
in the PDRN-3 and PDRN-3 + HMGB-1 groups also increased by 1.38 ± 0.11-fold and 0 88 ± 0.01-fold,
respe tively, compared with the sham group (* p < 0.05, ** p < 0.01; Figure 6B). These results indic ted
that PDRN administration st mulated wound healing by reducing inflammation and increasing
collagen synthesis. Furthermore, the effect of PDRN was reversed by HMGB-1 administration.
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collagen was significantly higher in the PDRN-3 group compared with the sham and PDRN-3 + 
HMGB-1 group (* p < 0.05, ** p < 0.01, *** p < 0.001). (B) Western blots for type I and type III collagen 
on Day 14. The PDRN-3 group also demonstrated higher collagen synthesis compared with the other 
groups. PDRN accelerated wound healing by promoting early collagen synthesis. This effect of PDRN 
was reversed by HMGB-1 administration (* p < 0.05, ** p < 0.01, *** p < 0.001). 
3. Discussion 
As an A2AR agonist, PDRN exerts angiogenic effects via vascular endothelial growth factor 
(VEGF) augmentation [19,20] and tissue-repair effects via fibroblast stimulation [21,22]. Additionally, 
the activation of A2AR has an anti-inflammatory effect due to the inhibition of several pro-
inflammatory mediators [16,18,23]. Previous investigations found that the injection of PDRN until 
the proliferative phase of wound healing resulted in a fibroplasia effect [20,22,24]. Although a 
fibroplasia effect from the prolonged injection of PDRN is beneficial to the compromised wound, it 
is not beneficial with respect to scar formation. Scar formation as the final result of wound healing is 
due to temporary overlaps of three phases: inflammatory, proliferative, and remodeling. In normal 
wound healing, there is an influx of inflammatory cells to the wound site until Days 4–6, followed by 
a proliferative phase during which inflammatory cells are replaced with fibroblasts. The transition 
between inflammation and proliferation is important because abnormal inflammatory prolongation 
results in excessive scarring [25]. Thus, we suspected that PDRN, which has both anti-inflammatory 
and collagen synthesis effects, could be beneficial in scar formation when administered during the 
inflammatory phase. Because uncontrolled and prolonged inflammation of the dermis produces 
pathologic scars, reduced inflammation and faster wound healing could have a beneficial effect on 
scar formation [4]. In this regard, we hypothesized that intensive administration of PDRN during the 
inflammatory phase for approximately three to seven days post-wounding could reduce 
inflammation and promote progression to the proliferative phase and early collagen synthesis. 
Minimizing inflammation is thought to be associated with reducing scar formation [26,27]. 
Continuous and histologically localized inflammation of the reticular layer of the dermis produces 
pathologic scars [4]. Similarly, it has been shown that in surgical wounds, dermal inflammation that 
persists for 1–2 weeks can result in aberrant scarring and eventually pathologic scars [4]. Thus, we 
attempted to determine the degree of inflammation after PDRN administration. CD45, which is also 
referred to as common leukocyte antigen, is a ubiquitous membrane glycoprotein expressed in all 
hematopoietic cells, except mature erythrocytes [28]. The degree of cellular infiltration was 
significantly greater in the sham group, and the majority of these cells were CD45+ leukocytes. To 
objectively analyze the infiltration of inflammatory cells, we counted cell numbers in H&E-stained 
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[30]. Extracellular HMGB-1 secreted from necrotic and inflammatory cells triggers inflammation by 
inducing inflammatory cell chemotaxis, which in turn initiates the production of pro-inflammatory 
Figure 6. (A) Western blots for type I and type III collagen on Day 7. The expression of type
I and III collagen was significantly higher in the PDRN-3 group com ared with the sham and
PDRN-3 + HMGB-1 group (* p < 0.05, ** p < 0.01, *** p < 0.001). (B) Western blots for type I and
type III collagen on Day 14. The PDRN-3 group also demonstrated higher collagen ynthesis compared
with the other groups. PDRN accelerated wound healing by promoting early collagen synthesis.
This effect of PDRN was reversed by HMGB-1 administration (* p < 0.05, ** p < 0.01, *** p < 0.001).
3. Discussion
As an A2AR agonist, PDRN exerts angiogenic effects via vascular endothelial growth
factor (VEGF) augmentation [19,20] and tissue-repair effects via fibroblast stimulation [21,22].
Addi ionally, the activation f A2AR has a anti-inflammato y effect due to the inhibition of several
pro-inflammatory mediators [16,18,23]. Previous investigations found that the inj ction of PDRN
until the proliferative phase of wound healing resulted in a fibroplasia effect [20,22,24]. Although a
fibroplasia effect from the prolonged injection of PDRN is beneficial to the compromised wound, it is
not beneficial with respect to scar formation. Scar formation as the final result of wound healing is
due to temporary overlaps of three phases: inflammatory, proliferative, and remodeling. In normal
wound healing, there is an influx of inflammatory cells to the wound site until Days 4–6, followed by
a proliferative phase during which inflammatory cells are replaced with fibroblasts. The transition
between inflammation and proliferation is important because abnormal inflammatory rolongation
results in excessive scarring [25]. Thus, we suspected that PDRN, which has both ant -inflammatory
and collagen synthesis effects, could be beneficial in scar formation when administered during the
inflammatory phase. Because uncontrolled and prolonged inflammation of the dermis produces
pathologic scars, reduced inflammation and faster wound healing could have a beneficial effect on
scar formation [4]. In this regard, we hypothesized that intensive administration of PDRN during the
inflammatory phase for approximately three to seven days post-wounding could reduce inflammation
and promote progression to the proliferative phase and early collagen synthesis.
Minimizing inflammation is thought to be associated with reducing scar formation [26,27].
Continuous and histologically localized i flammation of the reticular layer of the dermis produces
pathologic scars [4]. Similarly, it h s b en shown that in surgical wounds, dermal inflammation that
persists for 1–2 we ks ca result in aberrant scarring and eventually pathologic scars [4]. Thus, we
attempted to determine the degree of inflammation after PDRN administration. CD45, which is also
referred to as common leukocyte antigen, is a ubiquitous membrane glycoprotein expressed in all
hematopoietic cells, except mature erythrocytes [28]. The degree of cellular infiltration was significantly
greater in the sham group, and the majority of these cells were CD45+ leukocytes. To objectively
analyze the infiltration of inflammatory cells, we counted cell numbers in H&E-stained tissues. The scar
areas in the sham group were more abundantly infiltrated with inflammatory cells than those in the
PDRN-treated groups. Hence, our results indicated that the administration of PDRN could decrease
inflammation, which may be a factor in excessive scar formation.
HMGB-1 is a ubiquitous nuclear protein that exists in eukaryotic cells [29]. Extracellular HMGB-1
regulates the synthesis of monocyte-derived pro-inflammatory cytokines such as TNF-α and IL-1 [30].
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Extracellular HMGB-1 secreted from necrotic and inflammatory cells triggers inflammation by inducing
inflammatory cell chemotaxis, which in turn initiates the production of pro-inflammatory cytokines by
other inflammatory cells [12,31]. In previous investigations, administration of PDRN down-regulated
the expression of the inflammatory cytokine HMGB-1 in arthritis and periodontitis models [16,18].
Although the relationship between HMGB-1 and scar formation remains unclear, HMGB-1 induced
scar formation when applied to early embryonic murine skin wounds [32]. Thus, we hypothesized
that PDRN may down-regulate inflammation and scar formation in surgical wounds by suppressing
HMGB-1. On Day 7, extracellular HMGB-1 expression was widespread throughout the granulation
tissue in all treatment groups, particularly in the sham group. On Day 14, extracellular HMGB-1
expression remained apparent in the sham group but was decreased in the PDRN treatment groups.
Thus, our results implied that PDRN administration reduced HMGB-1 as a potent inflammatory
mediator. To confirm the role of HMGB-1 in PDRN action, we administered HMGB-1 to the PDRN-3
group. This additional HMGB-1 administration counteracted the effects of PDRN, resulting in a wide
scar area. Furthermore, collagen synthesis was also significantly suppressed by the administration
of HMGB-1 to PDRN-treated rats. Inflammatory cell infiltration was also increased on Day 14 in
PDRN-treated rats that were administered HMGB-1. Therefore, HMGB-1 could reverse the collagen
synthesis and anti-inflammatory effects of PDRN. These results supported our hypothesis that PDRN
exerts its anti-inflammatory and collagen synthesis effects via HMGB-1 suppression.
Histologic analyses of tissue samples collected on Day 7 showed that all groups were in the
early proliferative phase, as indicated by the formation of granulation tissue; however, substantial
inflammatory cell infiltration was observed in the sham group, which continued to exhibit granulation
tissue and inflammatory cell infiltration on Day 14. Furthermore, the scar widths were significantly
narrower in the PDRN-treated groups than in the sham group. PDRN could reduce the granulation
tissue that serves as potential scar tissue during the early wound-healing phase. Thus, PDRN prevents
scar formation via the promotion of fast wound healing by suppressing inflammation and enhancing
collagen synthesis.
In summary, we concluded that faster wound healing and decreased scar formation were induced
by the anti-inflammatory and collagen synthesis effects of PDRN. However, the short experimental
period could be a potential limitation of our study. Nonetheless, it was obvious that the reduced
formation of granulation tissue and decreased infiltration of inflammatory cells combined with faster
wound healing following PDRN administration could improve the characteristics and sizes of scars.
4. Materials and Methods
4.1. Animal Model
Twenty-four male Sprague-Dawley (SD) rats were used to study incisional wounds. All animal
protocols used in this study were approved by the Yonsei University Institutional Animal Care and
Use Committee (16 April 2014). General anesthesia was induced via intraperitoneal injection of a
zolazepam tiletamine mixture (30 mg/kg, Zoletil®; Virbac, Carros, France) and xylazine (10 mg/kg,
Rompun®; Bayer, Leverkusen, Germany). A 6 × 1 cm2 rectangular design was made to excise the
skin and the panniculus carnosus muscle. The skin and panniculus carnosus muscle were excised,
and only the skin layer was closed to maximize tension stress by leaving the muscle layer unrepaired.
After surgery, the rats were randomly assigned to one of three treatment groups: sham (n = 8), PDRN-3
(n = 8), and PDRN-7 (n = 8). The sham group was injected with 1 mL of normal saline for seven
days, whereas the PDRN-3 and PDRN-7 groups were administered PDRN via intraperitoneal injection
(8 mg/kg, Placentex Integro®, Mastelli SRL, Sanremo, Italy) for three and seven days, respectively.
Another experiment was performed to clarify whether the effects of PDRN on scar diminishing
and inflammation were mediated by HMGB-1. To determine whether HMGB-1 administration
increased scar formation and inflammatory cell infiltration, 400 µg of HMGB-1 (HMGBiotech, Milan,
Italy) diluted in 500 µL of normal saline was administered on a central 2-cm area of the incisional
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wound via intradermal injection for three days followed by PDRN administration as described for the
PDRN-3 group (PDRN-3 + HMGB-1 group; n = 6). HMGB-1 was administered before intraperitoneal
injection of PDRN. Other experimental protocols were the same as described above.
4.2. Histologic Analysis
Four SD rats in each group were euthanized on Days 7 and 14, and tissue biopsies were performed
to evaluate inflammatory cell counts and scar areas. Tissue samples (10 mm thick) were obtained
from the middle region of the wound, where there was maximal tension. All tissues were fixed in 10%
neutral buffered formalin, embedded in a paraffin block, and stained with H&E and M-T stain.
The H&E- and M-T-stained tissues were examined under a light microscope at 40× to estimate the
scar areas and the degree of tissue granulation. The scar area was estimated using ImageJ® software
version 1.49 (National Institutes of Health, Bethesda, MD, USA). In each wound, the scar and/or
granulation tissue areas were obtained from two tissue sections representing different areas of the same
wound. The mean scar and/or granulation tissue areas for each wound were then converted from pixel
numbers to square micrometers that were calculated using the ratio of pixel numbers to the scale bar.
The H&E-stained tissues were also examined using a light microscope at 400× to evaluate the
degree of inflammatory cell infiltration in the scar tissue. The inflammatory cells were counted in
four serial sections of tissue from within the dermis of the scar area. The numbers of inflammatory
cells were calculated for each wound from two tissue sections representing different areas of the same
wound, and then the mean number of inflammatory cells was obtained.
4.3. Immunohistochemistry for HMGB-1
Tissues obtained from the middle region of the wound were fixed with 10% formaldehyde
and embedded in a paraffin block. Tissue sections were pretreated with a 3% hydrogen peroxide
solution for 10 min to block endogenous peroxidase activity and then treated with a protein blocking
serum-free reagent (X0909 DAKO, Carpinteria, CA, USA) for 30 min to prevent non-specific reactions.
The sections were incubated at 4 ◦C overnight with primary antibodies (HMGB-1, Abcam, Cambridge,
MA, USA) and then incubated at room temperature for 20 min with secondary antibodies from the
DAKO Envision Kit (DAKO, Carpinteria, CA, USA). The expression of HMGB-1 in the scar area was
semi-quantitatively analyzed using the MetaMorph® image analysis software version 7.8 (Universal
Imaging, West Chester, PA, USA).
4.4. Immunofluorescence Assay for CD45
For immunofluorescence microscopy, the samples were blocked with 1% bovine serum
albumin (BSA) followed by incubation with anti-CD45 (Life Technologies Co., Carlsbad, CA, USA)
overnight at 4 ◦C. The next day, the cells were washed in phosphate-buffered saline and incubated
with an Alexa Flour 488-conjugated goat anti-rabbit immunoglobulin G secondary antibody for
60 min at room temperature. The final antibody treatment also contained tetramethylrhodamine
isothiocyanate–conjugated phalloidin and 4′,6-diamidino-2-phenylindole stain (DAPI; both at 1 g/mL;
Sigma, St. Louis, MO, USA) for nuclear staining. The slides were mounted in Vectashield® HardSet
Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA), and the cells were viewed
under a confocal laser scanning microscope (LSM700; Carl Zeiss MicroImaging, Thornwood, NY, USA)
4.5. Western Blots for Type I and Type III Collagen
The wound homogenates were analyzed via Western blotting. The protein concentration was
quantified using a bicinchoninic acid assay (Thermo Fisher Scientific, Waltham, MA) and normalized
to a standard concentration using extraction buffer. The proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene
difluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked for 1 h with
3% BSA in 1X TBST and then incubated overnight at 4 ◦C with monoclonal mouse anti-collagen type I
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α1 and α2 antibodies and anti-collagen type III α1 and α3 antibodies (1:1000, Abcam, Cambridge, MA,
USA). The primary antibody was detected using a horseradish peroxidase-conjugated goat anti-mouse
or anti-rabbit secondary antibody (1:5000, Cell Signaling, Beverly, MA, USA). The protein bands were
visualized using an ECL detection kit (Thermo Fisher Scientific, Waltham, MA, USA) according to
the manufacturer’s instructions. Finally, immunoblot signals were analyzed using ImageJ® software
version 1.49 (National Institutes of Health, Bethesda, MD, USA). The results from each group were
expressed as the integrated intensity relative to the sham group, measured with the same batch.
4.6. Statistical Analysis
Each measurement is shown as the mean ± SEM. All pairwise differences between the group
measurements were examined by independent and paired t-tests using standard software (SPSS for
Windows v15.0; SPSS Inc., Chicago, IL, USA). Statistical significance was set at p < 0.05.
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